News
$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%
Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of care
Company will host a conference call at 4:15 p.m. ET today
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%
Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of care
Company will host a conference call at 4:15 p.m. ET today
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
InsatiaBull : Thank you for re posting that! I don’t think people are getting the word
I was surprise to just watch it go down
Trytosaveabit OP InsatiaBull : You’re very welcome!believe that 10% drop was a short attack? GL and big profits to ya![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")